Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34‐selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis
暂无分享,去创建一个
M. Pillon | P. Marson | L. Caenazzo | C. Messina | S. Cesaro | E. Calore | L. Zanesco | G. De Silvestro | S. Varotto | R. Destro | Maria Vittoria Gazzola | M. Gazzola
[1] C. Craddock,et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.
[2] F. Frassoni,et al. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM) , 2001, Bone Marrow Transplantation.
[3] P. Thall,et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.
[4] M. Dürken,et al. Bone Marrow Transplantation in Hemophagocytic Lymphohistiocytosis , 2001, Leukemia & lymphoma.
[5] A. Fischer,et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.
[6] N. Kröger,et al. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single‐centre experience of 12 patients , 1999, British journal of haematology.
[7] A. Fischer,et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. , 1999, American journal of human genetics.
[8] P. Sham,et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. , 1999, American journal of human genetics.
[9] M. Martelli,et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.
[10] M. Steinbuch,et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. , 1997, Blood.
[11] R. Egeler,et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.
[12] A. Fischer,et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. , 1996, Leukemia.
[13] J. Klein,et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. , 1996, Bone marrow transplantation.
[14] S. Bearman,et al. The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.
[15] G. Vassal,et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. , 1992, Bone marrow transplantation.
[16] F. Appelbaum,et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.